Company Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians.
The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
| Country | United States |
| Founded | 2014 |
| IPO Date | May 18, 2016 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Paul LaViolette |
Contact Details
Address: 601 Brickell Key Drive, Suite 1080 Miami, Florida 33131 United States | |
| Phone | 510 906 4600 |
| Website | pulsebiosciences.com |
Stock Details
| Ticker Symbol | PLSE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001625101 |
| CUSIP Number | 74587B101 |
| ISIN Number | US74587B1017 |
| Employer ID | 46-5696597 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Paul Arthur LaViolette | President, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer and Co-Chairman of the Board |
| Robert W. Duggan | Executive Co-Chairman |
| Darrin R. Uecker | Chief Technology Officer and Director |
| Mitchell E. Levinson | Chief Strategy Officer |
| Kevin P. Danahy | Chief Commercial Officer and Principal Executive Officer |
| Jon Skinner | Chief Financial Officer |
| Edison Manuel | Vice President of Operations |
| Dr. Richard Nuccitelli Ph.D. | Chief Science Officer |
| Kenneth B. Stratton Esq., J.D. | General Counsel and Corporate Secretary |
| Patty Perla | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 28, 2025 | 8-K | Current Report |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 4, 2025 | 8-K | Current Report |
| Jan 23, 2025 | 8-K | Current Report |
| Jan 14, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 26, 2024 | 8-K | Current Report |
| Dec 19, 2024 | SCHEDULE 13D/A | Filing |